A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
Bladder Cancer|Urothelial Carcinoma
DRUG: Evorpacept|DRUG: Enfortumab Vedotin
First Cycle Dose limiting toxicities (DLTs), Up to 28 days|Adverse Events (AEs) as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v. 5.0)), timing, seriousness, and relationship to study therapy, Up to 24 months|Phase 1: Recommended Phase 2 Dose (RP2D), To identify the RP2D of ALX148 in combination with enfortumab vedotin, Up to 15 months
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.